Breakthrough Drug approved by FDA for HDV..

General
1

Chronic Hepatitis Delta Virus (HDV) infection is the most severe form of virus infection affecting 12-20 million people worldwide. HDV only infects individual who are already infected with Hepatitis B Virus (HBV). Patients with chronic HDV experience accelerated progression to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and death compared with HBV infection alone. Untill recently treatment options were extremely limited and largely dependent on interferon based therapies with modest efficacy and significant adverse effects. FDA recently approved Bulevirtide-gmod as treatment for chronic HDV infection.

Bulevirtide is basically a inhibitor blocking the NTCP receptor on hepatocytes. The NTCP receptor serves as a entry point for both HBV & HDV into liver cells. By preventing viral entry Bulevirtide reduces viral spread and controls disease progression.

The FDA approved Bulevirtide for adults with chronic HDV infection who have either no cirrhosis or compensated cirrhosis. This drug is administered as a once daily subcutaneous injection.

Key findings of study put forward in support of Bulevirtide included: on immediate treatment good outcomes in combined virologic and biochemical response, progressive HDV RNA suppression and ALT normalisation. Long term follow up demonstrated increasing rates of undetectable HDV RNA with continued treatment, suggesting sustained antiviral activity.

The approval of Bulevirtide changes the treatment landscape for HDV infection. For the first time, clinicians have access to targeted antiviral therapy specifically developed for HDV. This is especially important because HDV is associated with substantially high morbidity and mortality than HBV mono infection.

Comment on other novel regimen in development for HDV infection.

Reference List

  1. U.S. Food and Drug Administration. FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection. May 22, 2026.
  2. Anderer S. FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection. JAMA. 2026. doi:10.1001/jama.2026.8292.
  3. Reuters. Gilead’s drug wins first-ever US approval for deadly liver infection. May 22, 2026.
  4. Mullard A. Antiviral peptide nabs FDA approval for hepatitis delta virus infection. Nat Rev Drug Discov. 2026.
1 Like